Italy's Recordati H1 revenue rises 6.6% on rare diseases segment growth

Recordati Industria Chimica e Farmaceutica

28/07/2026 17:19

Overview
Italy pharma group's H1 2026 revenue rose 6.6%, driven by rare diseases segment
Adjusted net income for H1 2026 increased 6.7% year-over-year
Company confirmed full-year 2026 financial targets

Outlook
Recordati confirms FY 2026 net revenue guidance of €2.73–2.8 bln with FX headwind of ~-3.5%
Company expects FY 2026 EBITDA of €995–1,030 mln; margin +/-36.5% with FX headwind of ~-4.0%
Recordati sees FY 2026 adjusted net income of €655–685 mln; margin +/-24.0%

Result Drivers
RARE DISEASES GROWTH - Co said rare diseases revenue rose 17.1%, led by strong volume growth in Endocrinology and Hema-Oncology franchises
ISTURISA PERFORMANCE - Isturisa revenue grew 58%, driven by new patient uptake in the U.S. and expanded physician adoption
ADVERSE FX IMPACT - Co reported a €34.5 mln negative currency effect, mainly from U.S. dollar and Turkish lira devaluation

Company press release: ID:nGNE5BvNXP

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
EUR 1.41 bln
 
H1 Adjusted Net Income
 
EUR 349.9 mln
 
H1 Net Income
 
EUR 269.7 mln
 
H1 EBITDA
 
EUR 540.2 mln
 
H1 Free Cash Flow
 
EUR 299.4 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Recordati Industria Chimica e Farmaceutica SpA is €57.50, about 11.8% above its July 27 closing price of €51.45
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago

Reuters Recommended Reads
July 28 - Recordati first-half core profit rises 8.8% on rare diseases
July 27 - AstraZeneca Q2 revenue rises 6% on demand for its cancer therapies
July 28 - GSK launches $2.5 billion savings drive to fund faster drug development

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)